rais price target aimovig liberti
data support fda approv
view see liberti result episod migrain
support aimovig fda approv prospect ahead may
pdufa data increas po view
data ad valu proposit cgrp class
anticip could aid payer recept eas anticip
takeaway today market close report posit top-lin
result aimovig liberti trial episod migrain patient
experienc prior migrain treatment failur top-lin
press releas void specif studi statist signific
primari endpoint proport patient experienc least
reduct monthli migrain day well secondari
includ reduct monthli migrain day reduct day need
acut rescu medic improv mpfid qol score
respond rate taken togeth data continu build
upon robust dataset gener cgrp class
aid build cgrp market first-to-market entrant
engag payer aimovig reimburs criteria price
step edit increas po assumpt aimovig
increas confid fda approv result
increas price target
liberti data increas patient access aimovig lesser
reimburs restrict specif anticip posit data
gener saw benefit experienc treatment failur
littl two prior therapi could lessen step edit
requir payer could otherwis impos await manag
guidanc regard whether liberti data incorpor
aimovig bla view dataset advantag
compani negoti payer set price bar
cgrp class
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
valu dcf basi use wacc
view trade appropri valu price-to-earnings
forward price-to-earnings basi vs peer similar growth
prospect discount project revenu
adjust revenu pipelin product contribut
revenu contribut cash contribut
sh result price target support
upsid scenario assum longer-than-
expect delay entranc biosimilar
market slower-than-expect revenu eros
base busi higher-than-expect uptak repatha
downsid scenario assum faster
expect market entri biosimilar lead greater
market share eros price pressur
base busi regulatory/litig setback
biosimilar franchis continu slow uptak repatha
see limit forward month growth emerg
pipelin yet fill shoe amgn matur product
eros see inexpens biotech compani
rel basi price-to-earnings vs lg-cap average
like dividend perspect steadi cash flow
price-to-earnings price-to-earnings despit headwind base
busi despit see risk amgn recent
upsid slower product eros remain
sidelin
biosimilar remain major part valuat see
amgn intern pipelin biosimilar major revenu
ep driver though remain slightli cautiou
street launch time view recent setback
humira biosimilar indic challeng launch
environ initi anticip model amgn
biosimilar launch remicad rituxan avastin
herceptin humira see launch ahead
upsid model
launch repatha upcom
focu emerg pipelin becom construct
launch
omecamtiv erenumab key driver off-set base
busi eros see repatha uptak
signific driver close monitor rx share
upcom catalyst pdufa date aimovig migrain
risk factor neg influenc valuat
rate greater-than-expect competit core
busi franchis lower-than-expect uptak
grow busi develop regulatori setback
late-stag pipelin product/biosimilar franchis
compani report capit market estim
incom product total product product product cost expens non oper incom ebit non tax tax net ep ep ep ep exhibit dcf valuat
compani report capit market estim
discount rate equiti growth rate mm except per-shar data discount add add effect add termin
valu dcf basi use wacc view trade
appropri valu price-to-earnings forward price-to-earnings basi vs peer similar growth
prospect discount project revenu market product contribut
sh discount risk-adjust revenu pipelin product contribut
revenu contribut cash contribut result price target
support sector perform rate
risk rate price target
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
global biotechnolog compani focus develop manufactur
commerci novel biotherapeut primarili cancer nephrolog inflammatori
diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug
compani core busi erythropoietin epo stimul agent esa
epogen aranesp neutrophil stimul neulasta franchis
obtain princip inflammatori diseas busi enbrel acquisit
immunex go forward compani primari futur growth driver repatha
